Michael Makris/LinkedIn
Jan 19, 2026, 14:17
Michael Makris on The Benefits of Low-Dose Emicizumab in Hemophilia A
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn:
”Another study showing the benefit of low-dose emicizumab (Hemlibra) in hemophilia A.
The patients were receiving half the approved dose of the drug.
Despite this, the mean Annual Bleed Rate (ABR) was 0.4, the median was 0.0 and 67% had zero bleeds.
If you saw these data, you would not know that the patients were only using half the approved dose.
Is it not time for a randomised study in Europe or North America of full vs half-dose emicizumab in severe hemophilia A?
Roche will clearly never do such a study, it will need to be done independently.”
Stay updated with Hemostasis Today.
-
Feb 12, 2026, 16:36Tagreed Alkaltham: Tranexamic Acid in PBM
-
Feb 12, 2026, 16:35Paul Lambis Announces Maria Hadjidemetriou as a Speaker at Cyprus Diaspora Forum
-
Feb 12, 2026, 16:34Rahul Bhargava: Breaking Myths About Bone Marrow Transplant
-
Feb 12, 2026, 16:29Arun V J: Can You Be A Doctor And Still Be Stupid?
-
Feb 12, 2026, 16:26Changing the Narrative Around PPH – End Postpartum Hemorrhage
-
Feb 12, 2026, 16:20Mahesan Subramaniam: The Protective Switch in Brain Immune Cells Could Slow Alzheimer’s Disease
-
Feb 12, 2026, 16:13Lale Tokgözoğlu: Top 10 Dyslipidemia Papers of 2025
-
Feb 12, 2026, 16:10Neelam Mohan: Breaking Down Anemia from Causes and Testing to Treatment and Prevention
-
Feb 12, 2026, 16:04Irma Bagdoniene: From Estimating Risk to Seeing Disease in Preventive Cardiology